Protagonist Therapeutics Priced, Nasdaq: PTGX

Developing peptide-based oral drugs for inflammatory bowel disease.

Industry: Health Care

Latest Trade: $12.51 0.00 (0.0%)

First Day Return: -2.5%

Return from IPO: +4.3%

Industry: Health Care

We are a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Our primary focus is on developing first-in-class oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs. Compared to injectable antibody drugs, our oral peptides offer targeted delivery to the gastrointestinal tissue compartment, potential for improved safety due to minimal exposure in the blood, improved convenience and compliance due to oral delivery, and the opportunity for earlier introduction of targeted therapy for inflammatory bowel disease. Our initial lead product candidates, PTG-100 and PTG-200, are based on this approach, and we believe they have the potential to transform the existing treatment paradigm for IBD, a GI disease consisting primarily of ulcerative colitis and Crohn’s disease.
more less
IPO News for Protagonist Therapeutics
more
IPO Data
IPO File Date 07/11/2016
Offer Price $12.00
Price Range $11.00 - $13.00
Offer Shares (mm) 7.5
Deal Size ($mm) $90
IPO Data
IPO Date 08/10/2016
Offer Price $12.00
Price Range $11.00 - $13.00
Offer Shares (mm) 7.5
Deal Size ($mm) $90
Underwriters
more
Company Data
Headquarters Milpitas, CA
Founded 2001
Employees 29
Website www.protagonist-inc.com